The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Role of Formulation Vehicles in Taxane Pharmacology
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 882
Self-citationEisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E., Kerr, I., Vermorken, J. B., Buser, K., & Colombo, N. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2654 · Cited by 626
Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553
Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A., & Martini, C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2688 · Cited by 553
Central Nervous System Toxicity after Liver Transplantation
de Groen, P. C., Aksamit, A. J., Rakela, J., Forbes, G. S., & Krom, R. A. F. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710013171404 · Cited by 498
Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines
Liebmann, J., Cook, J., Lipschultz, C., Teague, D., Fisher, J., & Mitchell, J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.488 · Cited by 428
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., & Sartorius, S. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1692 · Cited by 426
Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kind
Verweij, J., Clavel, M., & Chevalier, B. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058903 · Cited by 361
Self-citation
Cited by
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Self-citationStrategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Protein nanoparticles as drug carriers in clinical medicine
Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.044 · Cited by 779
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Self-citationChiappetta, D. A., & Sosnik, A. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.03.022 · Cited by 567
Impact of Drug Transporter Studies on Drug Discovery and Development
Mizuno, N., Niwa, T., Yotsumoto, Y., & Sugiyama, Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.1 · Cited by 490
Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.612 · Cited by 488
Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs
Dong, Y., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.03.021 · Cited by 395
Drug interactions in cancer therapy
Scripture, C. D., & Figg, W. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1887 · Cited by 366
Feng, S.-S., & Chien, S. (2003) · Chemical Engineering Science · doi:10.1016/s0009-2509(03)00234-3 · Cited by 364
Gao, P., Rush, B. D., Pfund, W. P., Huang, T., Bauer, J. M., Morozowich, W., Kuo, M., & Hageman, M. J. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10511 · Cited by 361
Novel formulations of taxanes: a review. Old wine in a new bottle?
Hennenfent, K. L., & Govindan, R. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj100 · Cited by 345
Mikhail, A. S., & Allen, C. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.04.010 · Cited by 328
Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives
Scripture, C., Figg, W., & Sparreboom, A. (2006) · Current Neuropharmacology · doi:10.2174/157015906776359568 · Cited by 320
Self-citationProta, A. E., Danel, F., Bachmann, F., Bargsten, K., Buey, R. M., Pohlmann, J., Reinelt, S., Lane, H., & Steinmetz, M. O. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.02.005 · Cited by 314
Liggins, R. T., & Burt, H. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00016-9 · Cited by 286
Rafiei, P., & Haddadi, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s121881 · Cited by 284
Peltier, S., Oger, J.-M., Lagarce, F., Couet, W., & Benoît, J.-P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0022-2 · Cited by 274
Polymeric micelles in oral chemotherapy
Bromberg, L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.01.018 · Cited by 264
Mi, Y., Liu, Y., & Feng, S.-S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.02.022 · Cited by 261
Le Garrec, D., Gori, S., Luo, L., Lessard, D., Smith, D. C., Yessine, M.-A., Ranger, M., & Leroux, J.-C. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.06.018 · Cited by 255
“CrmEL and polysorbate 80 have also been shown to alter the pharmacodynamic characteristics of the solubilized drugs [1,2].”
BackgroundThe Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C. (2010) · Nanomedicine · doi:10.2217/nnm.10.113 · Cited by 164
Park, I. H., Sohn, J. H., Kim, S. B., Lee, K. S., Chung, J. S., Lee, S. H., Kim, T. Y., Jung, K. H., Cho, E. K., Kim, Y. S., et al. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.289 · Cited by 133
Bulitta, J. B., Zhao, P., Arnold, R. D., Kessler, D. R., Daifuku, R., Pratt, J., Luciano, G., Hanauske, A.-R., Gelderblom, H., Awada, A., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0827-2 · Cited by 47
Metadata
- Authors
- van Zuylen, L., Verweij, J., & Sparreboom, A.
- Venue
- Investigational New Drugs
- Published
- 2001-05
- Volume
- 19
- Issue
- 2
- Pages
- 125-141
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W1583373908
- Cited by
- 293
- References
- 70
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.